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 ABSTRACT 
 
Traumatic brain injury (TBI) is the leading cause of death and disability in the young 
population in the industrialized world. It comprises a heterogeneous group of brain 
pathologies where head trauma initiates a series of complex molecular pathways, 
which, together with the initial injury, account for the final outcome. Although 
extensive research has shed some light on these pathways, they are still 
incompletely understood. No pharmacological treatment for TBI exists. This project 
was initiated to study a possible impact of genetic heterogeneity in experimental TBI 
and identify genes/loci that regulate the secondary TBI pathways and outcome. 
 
Brain contusion was induced using the weight drop injury (WDI) model in inbred and 
congenic rat strains. Inflammatory pathways, infiltration of neutrophils, NK cells and 
monocytes/macrophages and activation of microglia and the complement pathway 
were found to be regulated by non-MHC (Major Histocompatibility Complex) genes. 
Non-MHC genes did also influence neurodegeneration, and interestingly, a stronger 
inflammatory response was correlated to a more vigorous neuronal/axonal injury 
and neurodegenerative outcome. Further, the use of congenic rats with loci 
harboring the Ciita gene or the MHC-gene complex, revealed that mainly MHC genes 
regulate MHC-II presentation after TBI with a smaller contribution from Ciita, and 
also that MHC genes regulate a delayed T cell infiltration after TBI, suggesting a role 
for adaptive immune responses and autoimmunity in TBI. 
 
We used various genetic mapping approaches to disclose genes that regulate 
neurodegeneration in a rat ventral root avulsion (VRA) model and found that 
glutathione-S-transferase alpha 4 (Gsta4) is a candidate gene for regulating 
motorneuron death in this model. Levels of Gsta4 were genetically regulated by a 
variation in the Gsta4 gene region and had an inverse correlation to the degree of 
neurodegeneration. This effect of Gsta4 gene variation was replicated in 
experimental TBI where it regulated the degree of hippocampal neuronal cell loss. 
Gsta4 exerts its effect possibly via more efficient detoxification of the highly reactant 
product of lipid peroxidation, 4-hydroxynonenal (4-HNE). The presence of 4-HNE 
was demonstrated in experimental TBI and also in human pericontusional tissue 
providing evidence for the importance of the Gsta4 – 4HNE pathway also in human 
TBI. Taken together, the findings in both VRA and TBI suggest that the Gsta4 - 4-HNE 
detoxification pathway can be important, not only in TBI, but possibly also in other 
neurodegenerative diseases.  
 
Alltogether, the findings of this thesis demonstrate that genetic heterogeneity has a 
substantial impact on the secondary pathways and outcome in experimental TBI and 
highlight the need for further research in the field of genetics in TBI.  
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 1 INTRODUCTION 
 
 
Traumatic brain injury (TBI) is one of the most prevalent causes of morbidity and 
mortality around the world and the leading cause of death and disability in young 
adults in the industrialized world. The overall incidence of TBI in Europe ranges 
between 100 and 300 per 100,000 inhabitants depending on country and study. This 
causes an enormous social and economical burden, both for the individual and the 
society, and underscores the necessity to develop effective treatment strategies 
(Gustavsson et al. 2011). In the last decades, many experimental and clinical studies, 
aimed to test and find pharmacological treatments for TBI, have been performed. 
Even if some of the pharmacological agents work in the experimental setting, all 
studies have failed to introduce an effective treatment for human TBI. 
 
Traumatic brain injury comprises a heterogeneous group and can include a wide 
range of vascular and/or parenchymal pathologies. Vascular injuries are classified as 
epidural, subdural, intracerebral and subarachnoidal hemorrhage, whereas 
parenchymal injuries are classified as focal contusions, lacerations and diffuse axonal 
injury. Motor vehicle accidents, falls, sports and violence are the main causes of TBI 
and lead to the primary injury, which is characterized by an acute mechanical brain 
tissue disruption. The severity and type of the primary injury determines the degree 
of acute cell death and is followed by a secondary phase with the activation of 
several pathophysiological pathways that can limit or aggravate the injury; hence 
both phases determine the outcome. The secondary phase starts within minutes 
after the injury and can continue for years after it, thereby providing a time window 
where therapeutic strategies can be introduced.  
 
The secondary injury cascades following traumatic brain injury, are complex and 
involve BBB breakdown, excitotoxicity, mitochondrial dysfunction as well as 
activation of inflammatory-, oxidative- and neurodegenerative pathways (Fig. 1). 
Moreover, it is becoming increasingly clear that the individual’s genetic predisposition 
can modify the response along these pathways. In this introduction, the secondary 
cascades that are relevant in the context of this thesis are reviewed, and data on the 
activation and role of these cascades in TBI are provided. Also, the current evidence 
on the role of genetics in TBI is reviewed.   
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Figure 1. Secondary injury cascades following TBI. 
 
 
 
1.1 INFLAMMATORY RESPONSE 
 
Historically, it was believed that the central nervous system (CNS) is protected from 
the immune system and has a limited possibility to evoke an inflammatory response 
because of its protection by the intact blood brain barrier (BBB). However, over the 
last decades, a rapidly growing body of evidence has demonstrated a wide range of bi-
directional interactions between the CNS and the immune system and thereby 
established the field of neuroimmunology (or neuroinflammation). With regards to 
TBI, the neuroinflammatory response is facilitated by the fact that the primary impact 
causes rapid disruption of the BBB and acute brain cell death. By now, several aspects 
of the inflammatory response in TBI have been investigated. The studies that are 
relevant for the investigations included in this thesis are summarized below. 
 
 
1.1.1 Immune Cells 
 
Traumatic brain injury results in a rapid destruction of the BBB allowing blood cells 
and serum components to enter the injured tissue. Neutrophils are the first cell type 
to enter the brain parenchyma and their migration is facilitated also by chemotactic 
factors such as CXCL1 and IL-8 and up regulation of adhesion molecules on the 
endothelium such as ICAM-1 (Bell et al. 1996; Carlos et al. 1997; Clark et al. 1996; 
Holmin et al. 1995; Szmydynger-Chodobska et al. 2009; Whalen et al. 1999). 
Neutrophils can release multiple proinflammatory molecules and depletion of these 
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cells reduces oedema formation and tissue loss after TBI (Kenne et al. 2012). 
Neutrophil infiltration is followed by monocytes/ macrophages that enter the injured 
tissue already at 24 hours but peak at 6-7 days after TBI as shown by 
immunohistological investigations (Holmin et al. 1995; Soares et al. 1995). However, it 
has to be noted that studies on these cells in TBI are difficult with immunohistology 
because cell markers such as ED-1 and OX-42 stain both monocyte- and microglia-
derived phagocytic cells. Monocytes/ macrophages can release immune mediators 
and phagocytose injured cells and debris. Lymphocytes and NK-cells have also been  
described in head trauma with some evidence about the role of B and T lymphocytes; 
albeit detailed knowledge about their function is still lacking (Clausen et al. 2007; 
Holmin et al. 1995; Holmin et al. 1998).  
 
In addition to the immune cells invading the brain from the periphery, host tissue 
immune cells are also activated after injury. Microglial cells are the primary immune 
cell mediators of the CNS response to injury, infection and disease. Microglia were 
first described by del Rio-Hortega in the early part of the 20th century and account for 
10 – 20% of the total cell population in the adult CNS. The origin of these cells has long 
been debated. Recent evidence shows that they belong to the mononuclear 
phagocyte lineage and invade the CNS during early development; as reviewed in 
(Kettenmann et al. 2011). Activation of microglia can be induced by systemic 
inflammatory factors, local CNS injury or chronic neurodegeneration and is 
accompanied by a change in their morphological phenotype (Cunningham et al. 2005). 
After brain trauma, microglia rapidly proliferate and migrate towards the lesion site, 
thereby establishing a barrier between the healthy and the injured tissue and 
constituting a first line host defense to the injury (Davalos et al. 2005). At the same 
time they can phagocytose the debris of damaged tissue, produce cytokines, 
chemokines and complement factors, upregulate MHC-II molecules and overall 
influence the inflammatory milieu in an either detrimental or beneficial way (Loane & 
Byrnes 2010; Nielsen et al. 2009). Astrocytes are the most abundant cell type in the 
CNS. Their primary role is to sustain homeostasis in the CNS and support the survival 
of neurons rather than to mediate inflammatory reactions. In response to injury 
astrocytes become hypertrophic, proliferate and migrate towards the borders of the 
lesion forming a reactive glial scar that isolates the injured area (McGraw et al. 2001). 
This sealing probably is a defence mechanism in order to protect the surrounding 
tissue from the damaging consequences. However, astroglial scaring can impede 
axonal growth and regeneration and thereby negatively affect outcome (Floyd & Lyeth 
2007; Ridet et al. 1997; Shechter et al. 2011). Also, it is now becoming increasingly 
evident that astrocytes, upon activation by inflammatory factors, serve several 
auxiliary immune functions such as the production of cytokines and chemokines 
(Brambilla et al. 2005; McKimmie & Graham 2010).  
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1.1.2 Cytokines and Chemokines 
 
Cytokines are small signaling molecules with inter-cellular activity that act upon cells 
and change their phenotype and activation status. Chemokines are small proteins that 
are produced and secreted by inflammatory cells to attract and recruit leukocytes. 
Cytokines are traditionally grouped into pro-inflammatory, such as IL-1b and TNF, and 
anti-inflammatory, such as IL-10 and TGF-b. However, for several cytokines, both 
deleterious and beneficial effects after TBI have been demonstrated. The dual role of 
cytokines with conflicting results between studies led to the use of the term “double-
edged sword” to describe the role of the immune system in TBI (Morganti-Kossmann 
et al. 2002). The role of cytokines and chemokines in TBI has been reviewed in (Helmy, 
A. et al. 2011) and (Ziebell & Morganti-Kossmann 2010). 
 
 
1.1.3 Complement Activation 
 
The complement system is a highly conserved molecular cascade that is important 
mainly in innate but also in adaptive immunity. It is synthesized by soluble molecules 
that are produced mainly in the liver and circulate in the blood. These molecules are 
widely involved in the chemotaxis of inflammatory cells and in direct tissue/cell 
damage. Activation of the complement system is induced by distinct trigger 
mechanisms that are used to distinguish the three different subpathways in the 
cascade: the classical pathway, the alternative pathway and the mannose-binding 
lectin pathway. All three pathways subsequently lead to the final formation of the 
membrane attack complex (MAC); for review see (Gasque 2004; Ricklin et al. 2010). 
Complement factors do not cross the intact BBB under physiological conditions, but 
they can enter and exert their functions in the injured CNS. Several studies have also 
demonstrated that all types of brain cells can produce complement factors with their 
subsequent deleterious or beneficial involvement in the local inflammatory response; 
for reviews see (Brennan et al. 2012; Helmy, Adel et al. 2011; van Beek et al. 2003; 
Yanamadala & Friedlander 2010).    
 
The production and involvement of complement mediators such as C3, C5a, CD55, 
CD59 and clusterin has been demonstrated in experimental TBI (Bellander et al. 1996; 
Leinhase et al. 2006b; Stahel et al. 2000). Furthermore, a number of studies have been 
performed utilizing genetically engineered animals or pharmacological intervention to 
elucidate the role of complement factors in TBI. Thus, following brain injury C3 and C5 
null mice displayed an attenuation of the inflammatory response, and C3 and C4 null 
mice exhibited a better motor outcome, while absence of the complement inhibitor 
CD59 exacerbated neuropathological outcome (Sewell et al. 2004; Yang et al. 2006; 
You et al. 2007). Factor B null mice, lacking a functional alternative pathway, showed a 
significant reduction of neuronal cell death and administration of anti-factor B 
antibody attenuated inflammation and apoptosis (Leinhase et al. 2006a; Leinhase et 
4 
 
al. 2007). Administration of C1-inhibitor improved the motor performance and 
reduced the contusion volume of brain injured mice (Longhi et al. 2009).  
 
In human TBI, Bellander at al found increased immunoreactivity against C1q, C3, C4 
C3b, C3d and C5b-9 on neurons in the penumbra region of the contused brain tissue 
2-82 hours after injury (Bellander et al. 2001). Furthermore, increased levels of C3, 
factor B and MAC have been demonstrated in the cerebrospinal fluid (CSF) of TBI 
patients (Bellander et al. 2011; Kossmann et al. 1997; Stahel et al. 1998; Stahel et al. 
2001). Taken together, these human studies combined with the experimental data 
clearly point towards detrimental effects of a dysregulated complement system after 
TBI. 
 
 
1.1.4 Major Histocompatibility Complex (MHC) 
 
The main functional role of MHC class I and class II molecules is to present peptides on 
the cell surface to CD8+ and CD4+ T cells, respectively. It is generally stated that 
peptides originating from intracellular sources are presented by MHC class I molecules 
in most cells of the body, while those originating from extracellular sources are 
presented by MHC class II molecules in specialized antigen presenting cells (APCs). 
However, some mechanisms, such as cross-presentation and autophagic degradation 
of peptides, have recently been described so that class I molecules present exogenous 
peptides and class II molecules present endogenous peptides, respectively; reviewed 
in (Crotzer & Blum 2010; Kurts et al. 2010; Neefjes et al. 2011; Vyas et al. 2008). 
Human MHC molecules are called human leukocyte antigens (HLA) and are equivalent 
to the H-2 molecules in mice and RT1 molecules in rat. The rat class II molecules RT1B 
and RT1D are equivalent to human HLA-DQ and HLA-DR, respectively. MHC genes are 
the most polymorphic genes present in the genome of every species (Ting & 
Trowsdale 2002). Class I molecules are expressed on all nucleated cells, while class II 
are expressed on professional APCs such as dendritic cells, macrophages and B 
lymphocytes. Each class II molecule consists of two integral membrane proteins 
named α and β chains. The α and β chains of all classical class II molecules have the 
same overall conformation consisting of 2 extracellular domains: α1 and α2, and β1 and 
β2, respectively. The membrane-distal domains combine to form a single peptide 
binding domain that displays a high level of polymorphism and can bind multiple 
peptides with high affinity and low specificity (Fig.2).  
 
The RT1 complex is encoded on rat chromosome 20 and contains the classical class I 
region (RT1-A), the class II region (RT1-B/D), the class III region, which harbors genes 
that are implicated in innate immunity (e.g. Tnf, C2, C4, Lta, Aif1, Ager) and the 
nonclassical (RT1-C/E/M) class I region, which encodes numerous molecules that are 
not fully characterized (xMHC) (Hurt et al. 2004; Tuncel et al. 2012). It should also be 
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noted that the rat RT1c haplotype expresses two RT1A (MHC-I) regions, while the 
RT1Av1 only one (Joly et al. 1996). 
 
MHC class I and II antigen presentation is increased in the contused and 
pericontusional tissue following both experimental and human TBI (Engel et al. 
2000; Holmin et al. 1995; Holmin et al. 1998; Oehmichen et al. 2009; Schwab et al. 
2001). The presence of MHC-II positive microglia has been also demonstrated along 
the corticospinal axis also at a distant site from the initial injury (Nagamoto-Combs 
et al. 2010). Zhang et al has shown that the up regulation of MHC class II molecules 
can be attenuated by administration of the anti-inflammatory drug FTY720 after 
brain contusion (Zhang et al. 2007). 
 
 
 
 
 
 
Apart from the above mentioned studies, no data up to date exist with regards to 
the regulation or effects of increased MHC-II presentation in head injury. One reason 
for this could be that the inflammatory reaction following TBI is considered to 
involve mostly the innate and less so the adaptive arm of the immune system.  
 
 
 
1.2 OXIDATIVE STRESS 
 
1.2.1 Oxidants 
 
1.2.1.1 Free Radicals 
 
Oxidative stress occurs when oxygen free radicals are generated in excess through the 
reduction of oxygen. A free radical is defined as any molecular species capable of 
independent existence that contains a number of unpaired electrons. Free radicals are 
shown to be involved in the pathophysiological cascades of many CNS diseases, 
Figure 2. Schematic illustration of 
the MHC class II molecule 
architecture and peptide presentation 
to CD4 lymphocytes. 
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including traumatic brain and spinal cord injury, stroke and chronic neurodegenerative 
diseases. Increased production of free radicals in CNS diseases is aided by the fact that 
the brain consumes about twenty percent of the total amount of oxygen in the body 
and also displays the highest oxygen metabolic rate of any organ in the body (Zauner 
et al. 2002).  
 
Two major categories of free radical species are the reactive oxygen species (ROS) and 
reactive nitrogen species (RNS). ROS include the superoxide radical (O2.-), hydrogen 
peroxide (H2O2) and hydroxyl radicals (OH.), while RNS include nitric oxide (NO) and 
peroxynitrite (ONOO-). Both the superoxide and the hydrogen peroxide radical are 
poorly oxidizing species, but they can generate the highly reactive hydroxyl radical 
through the Fenton and Haber-Weiss reactions. These reactions are catalyzed by free 
iron Fe (III) that is produced in the brain by the breakdown of hemoglobin or its 
release from intracellular ferritin. The hydroxyl radical can also be generated by the 
reaction of superoxide with nitric oxide and in this reaction peroxynitrite is also 
formed.  
 
The generation and role of free radicals have been demonstrated in numerous studies 
after TBI. Formation of superoxide and hydroxyl radicals in animal models of TBI 
induces various chemical and pathophysiological processes that lead to BBB 
dysfunction and mitochondria damage, as well as oxidative injury of DNA, proteins 
and lipids (Clark et al. 2001; Hall et al. 1993; Hall et al. 1994; Kontos & Povlishock 
1986; Kontos & Wei 1986; Smith et al. 1994; Zhang et al. 2012). Furthermore, up 
regulation of all three nitric oxide synthases (NOS: endothelial, neuronal and 
inducible) occurs after TBI as well as the formation of peroxynitrite (Cobbs et al. 1997; 
Gahm et al. 2000; Gahm et al. 2002; Hall et al. 2004). Substantial information about 
the role of free radicals in TBI has been also gained from experimental and clinical 
studies with antioxidant pharmacological agents; reviewed in (Bains & Hall 2012).   
 
   
1.2.1.2 Lipid Peroxidation 
 
Lipid peroxidation occurs when ROS target lipids to form lipid radicals (L•). Once lipid 
radicals are produced, they react with O2 to form peroxyl radicals (LOO•). Peroxyl 
radicals attack fatty acids (LH) to produce lipid hydroperoxides (LOOH) and new lipid 
radicals (L•), which in turn generate new LOO•; in this way the reactions propagate for 
a number of cycles to produce high numbers of LOOH (Fig. 3). Lipid peroxidation 
results also in generation of highly reactive aldehydes such as malondialdehyde 
(MDA), acrolein, oxidized phosphatidylcholine, 4-oxo-2-nonenal and 4-
hydroxynonenal (4-HNE, Fig. 3) (Adibhatla & Hatcher 2010).   
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Polyunsaturated fatty acids (PUFAs) are very susceptible to free radical attack, and 
since the CNS contains high levels of PUFAs, it is highly probable that lipid 
peroxidation occurs in the brain under oxidative conditions. Indeed, lipid peroxidation 
has been demonstrated in TBI by the thiobarbituric acid reactive substances (TBARS) 
assay or specific measurements of 8-epi prostaglandin F2a (8-epi PGF2a) or F2-
isoprostane. The TBARS assay measures TBA-reactive substances such as MDA and has 
been widely used in experimental TBI research (Santos et al. 2005; Saraiva et al. 2012; 
Toklu et al. 2009). However, the TBARS test is not specific and direct assays with HPLC 
are recommended to define the exact levels of MDA. TBARS concentrations and MDA 
levels are increased in the CSF during the first days of TBI and have been found to 
correlate to the severity of the injury (Bochicchio et al. 1990; Kasprzak et al. 2001). F2-
isoprostanes, one group of lipid peroxidation products derived from arachidonic acid, 
are initially formed in situ on membrane lipids and released by phospholipases in 
biological fluids (Morrow et al. 1990). F2-isoprostane has been detected in the CSF of 
brain injured patients where it displays an early peak at 24 hours, is higher in males 
compared to females, and is reduced by hypothermia (Bayir et al. 2002; Bayir et al. 
2004; Bayir et al. 2009; Clausen et al. 2012; Varma et al. 2003). Increased levels of 8-
epi PGF2a have also been found at 6 and 24 hours after TBI in rats (Tyurin et al. 2000). 
Although there are no reports about the presence of 4-HNE in human TBI, in the 
experimental setting it has been shown to be increased early after TBI (Ansari et al. 
2008; Gilmer et al. 2010; Readnower et al. 2010; Shao et al. 2006). Furthermore, 
antioxidant therapies against toxic pathways involving 4-HNE display a 
neuroprotective effect (Itoh et al. 2010; Sharma et al. 2010).   
 
 
 
 
Figure 3. Schematic illustration 
of the lipid peroxidation cycle 
initiation and propagation. 
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1.2.2 Antioxidants 
 
The endogenous antioxidant defense system of the CNS is constituted by low 
molecular weight molecules such as glutathione, ascorbate and α-tocopherol and 
antioxidant enzymes such as super oxide dismutase (SOD), catalase, glutathione 
peroxidases (GPXs) and glutathione S transferases (GSTs). 
 
 
1.2.2.1 Glutathione 
 
Glutathione consists of a tripeptide of glutamate, cysteine and glycine and is 
characterized by a reactive thiol group and a γ-glutamyl bond. It is the most abundant 
endogenous non-protein thiol antioxidant present in all the cells. Under physiological 
conditions glutathione exists mainly in its reduced form (GSH) and only in a very small 
amount in the oxidized state (GSSH). An increased GSSH/GSH ratio can be used as a 
sign of oxidative stress. GSH can directly scavenge free radicals or act as a co-substrate 
in the enzymatic reduction of H2O2 and products of lipid peroxidation such as lipid 
hydroperoxides and 4-HNE. GSH can then be regenerated from GSSG by the reaction 
catalyzed by glutathione reductase (GR), which transfers electrons from nicotinamide 
adenine dinucleotide phosphate (NADPH) to GSSG (Fig. 4A); for a review see (Dringen 
2000).  
 
 
 
 
Figure 4. Glutathione metabolism pathways: Lipid peroxides (L-OOH) and 4-HNE are produced during 
peroxidation of polyunsaturated fatty acids (PUFA) by reactive oxygen species (ROS). A) Reduced 
glutathione scavenges lipid peroxides to produce oxidized glutathione (GSSG).This reaction is catalyzed 
by glutathione peroxidase (GPX). GSH is then regenerated from GSSG with the use of NADPH. B) 
Reduced glutathione (GSH) scavenges 4-HNE to produce GS-HNE, a reaction catalyzed by GSTA4. GS-
HNE is then exported out of the cells by the Ral-interacting protein-76 (RLIP-76); modified from (Awasthi 
et al. 2004). 
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After experimental TBI, GSH levels in brain tissue decreased in the first days with 
lowest levels at 24 hours and with a concomitant increase in the glutathione oxidation 
ratio (GSSH/GSH) of 400% (Ansari et al. 2008; Chen et al. 2007; Tyurin et al. 2000). In 
infants and children with TBI, GSH levels in the CSF increased initially at day 1 and then 
decreased at days 5–7 as compared to controls. This was suggested to reflect an initial 
release of GSH into CSF from injured cells followed by a progressive decrease in cell 
antioxidant capacity (Bayir et al. 2002).  
 
 
1.2.2.2 Antioxidant Enzymes 
 
The antioxidant defense enzymes can be categorized in two groups based on the 
substrate: 1) the “first-line defense” enzymes such as SOD, catalase and GPXs that 
directly scavenge free radicals and 2) the “second-line defense” enzymes such as GPXs 
and GSTs that scavenge highly toxic molecules produced by free radical attack on 
DNA, proteins or lipids. SOD catalyzes the conversion of O2.- to H2O2 and catalase 
forms water and molecular oxygen from H2O2. GPXs are selenium containing enzymes 
that can both catalyze the reduction of H2O2 and the reduction of organic 
hydroperoxides to water or corresponding alcohols. They can therefore be a part of 
both the “first” and “second-line” antioxidant defense system. GPXs utilize reduced 
glutathione (GSH) as an electron donor (Fig. 4A).  
 
The activity of SOD was reduced early after experimental brain injury, suggesting a 
decrease in the tissue antioxidant capacity (Ansari et al. 2008). Also, overexpression of 
SOD-1 in transgenic mice resulted in both acute and long-term beneficial effects after 
brain trauma (Mikawa et al. 1996). Both increased and decreased GPX and catalase 
activity has been reported in experimental TBI (Ansari et al. 2008; Goss et al. 1997; 
Kerman et al. 2012). 
 
The GSTs comprise a complex and widespread enzyme superfamily that catalyzes 
the conjugation of exogenous and endogenous electrophilic substrates to 
glutathione. The classification of GSTs is based on a variety of criteria based on their 
amino acid sequence, location in the cell and substrate specificity as well as their 
immunological, kinetic and structural properties. Mammalian GSTs are highly 
polymorphic and can be divided in 7 subclasses: Alpha, Mu, Pi, Sigma, Theta, Omega, 
and Zeta; reviewed in (Sheehan et al. 2001). They are involved in multiple pathways 
such as in the clearance of carcinogens and thereby cancer pathogenesis, in drug 
resistance mechanisms, and they also act as protectors against oxidative stress by 
detoxifying highly toxic products of lipid peroxidation such as 4-HNE; reviewed in 
(Balogh & Atkins 2011; Landi 2000; Townsend & Tew 2003). 4-HNE can 
spontaneously react with the highly abundant GSH molecules in a reaction termed 
Michael addition. However, the reaction, when catalyzed by GSTs, can be 600 times 
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faster than the spontaneous reaction. It is now established that, of all the GSTs, Gsta4 
has by far the highest enzymatic capability of reducing 4-HNE (Fig. 3B) (Balogh & 
Atkins 2011; Engle et al. 2004; Siems & Grune 2003).   
 
 
 
1.3 NEURONAL DEATH AND AXONAL INJURY 
 
Neuronal death in TBI starts immediately during the injury with the mechanical 
disruption of the brain tissue. However, an important feature of TBI is that a high 
degree of the neuronal damage occurs in a secondary phase which starts directly after 
the initial injury and continues for up to a year or even longer (Williams et al. 2001). 
Criteria such as cell morphological changes, type of death inducers, specific molecular 
mechanisms and enzymatic-dependence have all been used to classify neuronal cell 
death after TBI; as reviewed in (Stoica & Faden 2010). Based on morphological criteria, 
two predominant forms of cell death have been described in head trauma: necrosis 
and apoptosis. However, autophagic death has also been described and there is also 
evidence that necroptosis might also be a form of neuronal cell death after TBI (Luo et 
al. 2011; Wang et al. 2012). Necrosis, originally believed to be the only form of cell 
death in TBI, is not energy dependent, occurs when the cell is severely damaged and is 
characterized by cell and organelle swelling, disruption of membranes and chromatin 
digestion. Apoptosis, originally described in 1972 by Kerr et al, is a term used to 
morphologically describe a programmed cell death mechanism that induces cell 
shrinkage, nuclear condensation, membrane blebbing and the formation of 
membrane vesicles that enclose cellular components (Kerr et al. 1972). During the last 
two decades, programmed cell death has been extensively described after TBI and 
several aspects of the molecules that induce or propagate apoptotic cell death have 
been characterized; among many studies (Keane et al. 2001; Newcomb et al. 1999; Ng 
et al. 2000; Rink et al. 1995; Wennersten et al. 2003) and as reviewed in (Raghupathi 
2004; Wong et al. 2005). It has to be emphasized that both inflammation and 
oxidative stress are key factors in neuronal cell death (Fatokun et al. 2008; Griffiths et 
al. 2009). 
 
Axonal injury in TBI is the predominant feature of a separate type of brain trauma: 
diffuse axonal injury (DAI). The term DAI is used to describe the histological features of 
axonal injuries that are mainly caused by head trauma where rapid acceleration and 
deceleration of the brain occurs. However, axonal injury can also be observed in focal 
injuries as a delayed axonopathy and/ or axotomy that results from structural changes 
in the cytoskeleton of the axon, at the vicinity of the injured site, but also in areas 
remote from the initial impact. Neurofilaments comprise a group of neuron-specific 
intermediate structural proteins that are the predominant component of the axonal 
cytoskeleton and are therefore important in axonal injury studies. Neurofilaments 
(NFs) are composed of three subunits based on their molecular weight: a) light (NFL), 
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b) medium (NFM) and heavy (NFH). Changes in the amount and alterations in the 
normal structure of NFs have been described after TBI. Studies with electron 
microscopy have shown that the predominant histological features of axonal injury, 
axonal bulbs and swellings, contain accumulated and misaligned NFs (Christman et al. 
1994; Posmantur et al. 1994; Posmantur et al. 2000). Also, NFH is detected in the CSF 
of patients with TBI and in some studies correlate to the severity of DAI and outcome 
(Siman et al. 2009; Zurek et al. 2011; Zurek & Fedora 2012).          
 
 
 
1.4 TREATMENT  
 
A significant part of neuronal death in TBI occurs in the secondary phase and this 
provides a therapeutic time window for neuroprotective treatment. At present, 
treatment of TBI consists of methods aimed to decrease raises in intracranial pressure 
and optimize cerebral perfusion to improve the oxygenation of the brain. As of today 
no pharmacological treatment with proven effect exists. This is in spite of great efforts 
directed at finding effective pharmacological agents. Many drugs have shown 
promising results in experimental TBI, but translation to humans has failed. Two 
widely acknowledged reasons for this are the faulty design of clinical trials and the fact 
that the complexity of human brain trauma cannot be mimicked by one single 
experimental TBI model. Other factors such as genetic predisposition and 
neurorehabilitation might also play a role; reviewed in (Maas et al. 2010a; Marklund & 
Hillered 2011). This has led to new recommendations as to the design and 
methodologies that should be used in future TBI clinical trials (Maas et al. 2010b). On 
the other hand, even if treatment has failed in the clinical context, the use of chemical 
compounds and pharmacological agents in experimental TBI has provided valuable 
information about the secondary injury pathways and their role regarding the 
outcome. It has to be emphasized that many of the drugs used in these studies target 
inflammatory and oxidative pathways; reviewed in (Marklund et al. 2006).   
 
 
 
1.5 INFLUENCE OF GENETIC BACKGROUND 
 
Recovery after TBI is variable even for patients with similar clinical characteristics and 
injury severity. Prediction of outcome is of major importance when taking decisions 
about the treatment of patients with TBI, particularly those with moderate to severe 
injury that are treated in intensive care units. The prognostic value of factors such as 
age, clinical severity and imaging characteristics of the injury are well studied and are 
thus used in predictive models. However, the relation of other factors to TBI outcome 
is less well identified (Lingsma et al. 2010). It is now becoming increasingly realized 
that the individual’s genetic predisposition also contribute to the recovery and 
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outcome after TBI. This has recently been highlighted in several review articles 
(Dardiotis et al. 2010; Dardiotis et al. 2012; Diaz-Arrastia & Baxter 2006; Jordan 2007; 
Kurowski et al. 2012; Weaver et al. 2012; Wilson & Montgomery 2007).  
 
Detailed data about the effect of genetic background on secondary injury cascades 
and outcome in experimental TBI is increasing in the last years, but despite this it is 
still scarce compared to other fields in neuroscience. Fox et al has demonstrated 
differences in behavioural outcome in three mouse strains while Witgen et al found 
no differences in hippocampal neuronal survival between two mouse strains differing 
at multiple loci in chromosome 4 (Fox et al. 1999; Witgen et al. 2006). Strain 
differences in the response to TBI have also recently been reported between Sprague–
Dawley and Fisher rats, with the latter displaying higher intracranial pressure, more 
seizure activity and worse motor deficits, but a better cognitive performance (Reid et 
al. 2010). In another study, Sprague–Dawley rats had a speedier behavioural recovery 
compared to Long–Evans rats (Tan et al. 2009). Finally, differences in immune cell 
infiltration and neurodegeneration have been demonstrated between the DA and PVG 
inbred rat strains (Bellander et al. 2010). 
 
In human TBI, the most extensively studied polymorphism is in the apolipoprotein E 
(APOE) gene. Apolipoprotein E is a 34 kilodalton protein that transports lipids between 
tissues and cells but also has been implicated in many other biological pathways (Kim 
et al. 2009; Mahley & Rall 2000). In humans APOE is encoded by a single gene on 
chromosome 19 and three common allelic variants (ε2, ε3, and ε4) which yield three 
distinct isoforms (APOE2, APOE3, and APOE4, respectively). The APO ε3 allelic variant 
is the most frequent in caucasian populations (Corbo & Scacchi 1999), while the APO 
ε4 allelic variant is associated with Alzheimer’s disease (Naj et al. 2011). The fact that 
TBI leads to amyloid deposition in the brain and increases the risk for developing 
Alzheimer’s disease led to further studies of the role of APOE in TBI; reviewed in 
(Sivanandam & Thakur 2012). Several studies using human APOE transgenic or 
knockout mice in models of TBI have shown an effect of the ε4 allelic variant in the 
inflammatory response, oxidative stress, oedema formation, amyloid deposition and 
outcome (Chen et al. 1997; Crawford et al. 2009; Hartman et al. 2002; Lomnitski et al. 
1997; Lynch et al. 2002). In parallel, association studies in human TBI patients have 
shown APOE4 to be connected to various injury parameters and a poor outcome after 
TBI. However, other studies have failed to replicate these findings. A meta- analysis of 
all these studies indicated that the APOE4 variant does not influence the initial injury 
parameters but is associated with a poorer outcome at 6 months after the trauma 
(Zhou et al. 2008).  
 
A smaller number of association studies have suggested an association of TBI 
outcome to polymorphisms in genes shown in table 1. Other studies show negative 
results for polymorphisms in interleukin-1a, interleukin-1b, interleukin-6 and NEFH 
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genes (Johnson et al. 2006; Tanriverdi et al. 2006). These studies point to specific 
genes influencing the pathology and/or outcome after TBI. However, several 
concerns exist as to the methodology and design used in such investigations since 
they allow a high risk for false positive or negative results (Diaz-Arrastia & Baxter 
2006; Hardy 2002; Sawcer 2010). This stems from the fact that the low number of 
patients included in association studies do not reach the necessary statistical power 
needed to confidently describe genetic influences. Furthermore, variation in patient 
selection, different ethnicities in the studied population, failure to control for 
confounders (for example age, injury severity, sex and treatment approaches) and 
variability in outcome parameters limit the ability to replicate these studies (Dardiotis 
et al. 2012). A limitation of these studies also emerges from the fact that only one 
gene polymorphism “of interest” is examined and this method cannot unravel additive 
effects or other gene polymorphisms of possibly stronger effect (Comings 2003). 
 
 
Gene Number of 
patients 
Outcome Parameter Study 
ACE 73 Cognition (Ariza et al. 2006) 
BDNF 
BDNF 
BDNF 
109 
168 
75 
Cognition  
Executive function 
Cognition 
(Rostami et al. 2011) 
(Krueger et al. 2011) 
(McAllister et al. 2012) 
CACNA1A mut 2 families Cerebral oedema (Kors et al. 2001) 
COMT 113 Executive function (Lipsky et al. 2005) 
DRD2 39 Cognition (McAllister et al. 2005) 
Interleukin-1b 
Interleukin-1b 
151 
69 
Brain hemorrhage 
GOS 
(Hadjigeorgiou et al. 2005) 
(Uzan et al. 2005) 
Interleukin-6 77 Survival (Dalla Libera et al. 2011) 
Neprilysin 81 Amyloid-beta plaques (Johnson et al. 2009) 
NOS3 51 Brain perfusion (Robertson et al. 2011) 
PARP-1 191 GOS (Sarnaik et al. 2010) 
P53 90 GOS (Martinez-Lucas et al. 2005) 
    
 
Table 1. Studies up to date suggesting an association of gene allelic variations with various outcome 
parameters after traumatic brain injury. (mut = mutation, GOS = Glasgow Outcome Scale) 
 
 
The best way to tackle this problem is by designing genome-wide association studies 
in well powered clinical materials, an approach that has revolutionized the field of 
genetics in other diseases. Identification of low risk loci that influence susceptibility to 
disease have thus provided important information in neurological diseases such as 
multiple sclerosis (MS), Parkinson’s and Alzheimer’s disease (Bras et al. 2012; Gandhi 
& Wood 2010; Sawcer et al. 2011). Although, a similar approach in TBI is feasible in 
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principle, the heterogeneity of the disease, including multiple and insufficient 
outcome measures, and lack of large size material collection make this difficult to 
achieve in a short term perspective. An alternative approach is to use animal disease 
models combined with forward genetics in order to identify genetic factors and 
address some of the above mentioned problems. The results of animal studies can 
reveal new candidate genes and point towards certain pathways that in turn can be 
tested for a possible relevance in human TBI. 
 
 
 
1.6 VENTRAL ROOT AVULSION AS A TOOL IN GENETIC STUDIES OF 
NEUROINFLAMMATION AND NEURODEGENERATION                                
 
Root avulsion in the rat mimics a specific type of plexus injury in humans and has thus 
been used to study surgical regenerative approaches in this disease (Carlstedt 2008). 
Avulsion of ventral roots transects motor axons at the very exit from the cord, thus at 
the interface of the peripheral and central nervous systems. The induced trauma 
results in a retrograde response in the spinal cord which is characterized by local 
activation of inflammatory cells and molecules, up or down regulation of neurotrophic 
factors, gliosis and motorneuron degeneration (Hammarberg et al. 1998; Koliatsos et 
al. 1994; Lundberg et al. 2001). The VRA model is simple and highly reproducible with 
a low degree of inter-individual variation. For this reason, it has been used with 
success as a model in forward genetics in order to identify genetic loci that regulate 
neuroinflammatory and neurodegenerative pathways in the CNS.  
 
Studies in inbred rat strains showed a sizeable degree of strain-dependent regulation 
of inflammation, gliosis and motorneuron degeneration after VRA (Lundberg et al. 
2001). This regulation was mostly accounted by variability in non-MHC genes (Olsson 
et al. 2000). Following from this, an F2 cross between the strain with highest and 
lowest motorneuron degeneration (DA and PVG, respectively) but also with 
differences in the local inflammatoty response such as MHC class II presentation, 
recruitment of T cells and glial activation, could disclose genetic loci that regulated 
these phenotypes. Two gene regions affecting neurodegeneration were detected: 
Vra1 on chromosome 8 with a significant linkage peak and Vra2 with a suggestive 
linkage and weaker effect on chromosome 5. Furthermore, MHC-II presentation was 
regulated by Vra4 with a very strong linkage peak on chromosome 10 and a 
significantly weaker effect of the MHC gene complex itself (Lidman et al. 2003). 
Subsequent studies showed that the gene that accounted for the effect of Vra4 on 
MHC-II presentation was the class II transactivator (Ciita or Mhc2ta) (Swanberg et al. 
2005). In addition, the effect of Ciita could also be replicated in the model of 
experimental autoimmune encephalitis (EAE) (Harnesk et al. 2008). Also, 
polymorphism in the type III promoter of the Ciita gene was associated with increased 
susceptibility to MS, providing evidence for a translational potential of the VRA-
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genetic approach in neuroinflammatory and neurodegenerative CNS diseases 
(Swanberg et al. 2005). 
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 2 AIMS OF THIS THESIS 
 
 
The purpose of this thesis was to study the impact of inherent genetic predisposition 
and further characterize gene regions that regulate inflammation and 
neurodegeneration in TBI as studied in the rat. The specific aims of this thesis are 
categorized as follows: 
 
 
 
 
1) Study the impact of genetic variability occurring among inbred rat strains 
on the biological response after TBI in the rat. 
 
 
2) Study the relative contribution of MHC and non-MHC mediated genetic 
effects on the biological response to TBI, with special emphasis on 
MHC-II presentation. 
 
 
3) Characterize and identify candidates in the Vra1 locus in a model of 
neurodegeneration. 
 
 
4) Characterize the effect of the Vra1 locus in experimental TBI. 
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 3 METHODOLOGICAL CONSIDERATIONS 
 
 
 
3.1 CHOICE OF EXPERIMENTAL MODELS 
 
3.1.1 Experimental Traumatic Brain Contusion (I, II and IV) 
 
In the present thesis we used the open skull weight drop injury (WDI) model, originally 
described by Feeney et al (Feeney et al. 1981), and we modified it as to produce a 
contusion in the rat parietal cortex above the hippocampus. The contusion device is 
composed of a stainless steel tube, a free falling weight and a piston attached to a 
stereotactic device. The weight moves freely in the tube that has air holes on the sides 
in order to avoid air compression. The anesthetized rat is placed on a stereotactic 
frame and a craniotomy is performed, 3 mm behind and 2.3 mm lateral to the 
bregma, with great care not to damage the dura. The footplate of the piston is 
positioned vertically on the exposed dura and the device is then lowered. The piston 
can freely be pushed back in to the tube by the exposed cortex/dura. The weight is 
then freely dropped from 7 cm and hits the piston that compresses the tissue at a 
maximum depth of 3 mm (Fig. 5). In sham operated control animals, surgery is 
finished after the craniotomy.   
    
 
 
 
 
Figure 5. Schematic illustration of the contusion device and the produced traumatic injury: A) the 
weight-drop device composed of the weight (24 g), the tube and the piston and positioned above the 
exposed dura; B) a magnified picture of the marked frame in A showing the cylindrical piston, with a 
diameter of 1.8 mm, moving freely in the tube and being able to compress the exposed brain tissue; C) 
the lesion produced by the weight-drop device with the contused cortex (Co), the pericontusional tissue 
(Pc), the underlying hippocampus (hi) and the third (3v) and lateral ventricle (lv).  
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Primary injury in human TBI is usually caused by two major mechanical phenomena: 1) 
a direct mechanical force that causes skull distortion and an underlying brain 
contusion or/and a contusion contralateral to the impact (contrecoup), 2) an indirect 
mechanical force that accelerates the brain tissue with relation to the skull or other 
surrounding structures and causes tissue distortion and tearing (O'Connor et al. 2011). 
These mechanical phenomena produce a wide range of brain tissue and vascular 
injuries, which explains the finding that several types of injury usually coexist in 
human TBI, including contusions, subdural and epidural hematomas, axonal injury and 
subarachnoidal hemorrhage. Over the last decades a wide range of animal models of 
TBI have been produced. These models can be classified: 1) according to the 
characteristics of the mechanical force to static, dynamic/direct and dynamic/indirect 
(Cernak 2005) or 2) according to the characteristics of the lesion to focal, mixed, 
diffuse and complex models (Marklund & Hillered 2011). An example of a static model 
is a cranial nerve crush injury (Kiernan 1985) and of a dynamic/indirect model is a blast 
injury (Risling et al. 2011) while the most commonly used dynamic/direct models are 
shown in table 1.      
 
 
 Dynamic/Direct Reference 
Focal Controlled cortical impact (CCI) 
Open skull weight drop injury (WDI) 
(Dixon et al. 1991) 
(Feeney et al. 1981) 
Mixed Lateral fluid percussion injury (lFPI) (McIntosh et al. 1989) 
Diffuse I/A “Marmarou” Model  
Central fluid percussion (cFPI) 
(Marmarou et al. 1994) 
(Dixon et al. 1987; McIntosh 
et al. 1987) 
Complex Combination of above models with hypoxia 
and/or hypotension 
(Ishige et al. 1987) 
 
Table 2. Examples of the most commonly used dynamic/direct experimental TBI models in the rat. The 
models are classified according to the characteristics of the lesion they produce. References for the first 
description of the model in the rat are given (for a review see Marklund and Hillered, 2011). 
 
 
All of the above models replicate one or several aspects of human TBI but no single 
model can reproduce the heterogeneity of clinical TBI alone. However, by providing 
reproducibility and control of injury parameters, access to the injured tissue, large 
sample sizes and possibility to modify the genotype, they have altogether been 
essential for understanding the pathophysiologic mechanisms that follow human 
brain trauma and also for testing various treatment approaches. The WDI model is a 
focal dynamic/direct experimental model that produces a highly reproducible lesion 
resembling a human contusion (Holmin et al. 1995; Holmin et al. 1998). Some 
concerns about WDI have been raised as to the 1) craniotomy performed prior to the 
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trauma, which does not resemble the clinical setting of closed trauma (Flierl et al. 
2009), 2) variation of the impact velocity and 3) the possibility of rebound trauma 
(O'Connor et al. 2011), the latter two as opposed to the similar CCI model. In this 
thesis a low height of 7 cm was used that minimizes both the variation of impact 
velocity and the possibility of a rebound effect. In addition, the WDI model is fast and 
pathophysiological changes are seen and can be studied in the contused cortex, the 
pericontusional cortex and the ipsilateral hippocampus and thalamus and at a lower 
degree in the contralateral hemisphere (Clausen & Hillered 2005; Holmin et al. 1995; 
Lewen et al. 1996).   
 
 
3.1.2 Ventral Root Avulsion (III) 
 
In the VRA model used in this thesis, the L3-L5 ventral roots have been teared away 
from the spinal cord resulting in a lesion at the border between the central and 
peripheral nervous system (PNS) (Fig. 6).    
  
 
 
 
 
The detachment of ventral roots initiates local pathophysiological mechanisms in the 
ventral horn of the spinal cord that subsequently lead to motorneuron degeneration. 
After VRA, the spinal cord was collected at different time points based on previous 
studies on the kinetics of glial reaction, inflammation and neurodegeneration (Piehl & 
Lidman 2001). Thus earlier time points (1-14 days) were used to assess 
pathophysiological pathways and a later time point (21 days) to assess the degree of 
neurodegeneration. Motorneuron loss was evaluated by counting the remaining 
motorneurons on the injured side of the spinal cord and comparing them to the 
number of neurons on the intact side. The motorneuron counting was initially 
performed on sections stained with cresyl violet. However, to avoid problems that 
arise from this type of profile counting, the counting methodology was later 
complemented with design-based stereology (see section 3.5.2).   
 
The VRA model was chosen to complement the genetic studies in this thesis due to 1) 
high reproducibility with a low degree of inter-individal variation as compared to the 
Figure 6. Schematic illustration in (A) 
and live image in (B) of the ventral 
root avulsion model where the L3-L5 
ventral roots are pulled from the 
spinal cord (B adopted from (Lidman 
et al. 2003)).  
  21 
 
WDI, characteristics that are advantageous in animal genetic studies and 2) the long 
experience and extensive knowledge of this model in our laboratory.        
 
 
 
3.2 HUMAN TRAUMATIC BRAIN INJURY BIOBANK (IV) 
 
In paper IV, we used CSF from our human TBI biobank. In 2007, we started collecting 
blood for DNA analysis, serum and CSF from patients that were treated in the 
neurointensive care unit. Informed consent was obtained from relatives to the 
patient. Collection of clinical data was obtained from the patient’s medical record. 
One hundred patients were included in the biobank until autumn 2010, when we 
started the analyses for 4-HNE in paper IV. By now, biological samples from 
approximately 170 patients are stored in the biobank. Unfortunately, we were not 
able to detect the targeted marker (4-HNE) in any of the CSF tested, but this biobank 
can now be used in subsequent analyses to translate results from this thesis in the 
human context. 
 
 
 
3.3 METHODS FOR GENETIC DISSECTION 
 
Studies on the contribution of genes and genetic loci on a disease phenotype can be 
performed by two approaches, forward or reverse genetics. The forward approach 
starts by identifying a disease phenotype, or quantitative trait, and thereafter tries to 
identify the specific genomic sequence(s), that account for the observed variation. The 
identified genomic region is termed a quantitative trait locus (QTL). In contrast, the 
reverse approach starts by identifying a specific gene variation/mutation and 
thereafter tries to find its contribution to a phenotype or biological mechanism. In the 
natural biological context, the former method is more likely to be successful to 
understand the genetic basis of common disease phenotypes. The main reason for 
this is that disease phenotypes are mostly affected by small/moderate contributions 
from several genes (i.e. in complex diseases) and single gene mutations are only in 
rare cases the cause of common disorders. In this thesis the forward approach was 
utilized since it is predicted and also supported from previous studies that quantitative 
TBI and VRA phenotypes are regulated by multiple genes with varying quantitative 
effects. 
 
3.3.1 Inbred Rat Strains and Crosses (I-IV) 
 
Genetic dissection of quantitative traits by forward genetics in animal models is 
performed by starting with two or more inbred rat strains that differ in a specific trait. 
Inbred rat strains are nearly identical and homozygotes at each locus in the genome. 
22 
 
Crossing of strains results in recombination and crossover between homologous 
chromosomes occurring during meiosis. Crossing of two inbred rat strains creates an 
F1 generation, where all individuals are identical heterozygotes at all loci. Further 
crossing of the F1 generation will result in an F2 intercross where all individuals are 
unique since recombination has occurred between the chromosomes (Figure 7). By 
determining the genetic composition and disease phenotypes in each of the F2 
individuals, a statistical probability that a certain genetic region is linked to a variation 
in the phenotype can be established; in this way a QTL is identified.  
   
 
 
Figure 7. Schematic illustration of the forward genetics breeding strategy used in this thesis; as 
discussed in the text. 
 
 
Subsequent and continuous intercrossing from the F2 generation will result in an 
advanced intercross line where more recombinations are accumulated and thereby 
smaller chromosome fragments can be identified as QTLs underlying the trait (Darvasi 
1995).  
 
In this thesis, we utilized two inbred rat strains, the Dark Agouti (DA) and Piebald Virol 
Glaxo (PVG), and crosses between them as shown in figure 7. These strains where 
chosen because of their differences in biological pathways and susceptibility to EAE 
and VRA. The DA strain is susceptible to EAE while the PVG strain is resistant and, 
similarly, the DA displays a stronger local inflammatory response and less 
motorneuron survival after VRA compared to the PVG.   
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3.3.2 eQTL Mapping (III) 
 
Any trait can be mapped with linkage analysis and a particular approach that has 
emerged in recent years is the mapping of gene expression QTLs (eQTLs). The recent 
technological advancement enables analysis of the expression of several thousand 
mRNA transcripts using microarray chips, and these data can be analyzed with linkage 
analysis in a global gene expression profiling approach. Combination of forward 
genetics and microarray data and analysis with eQTL mapping can give information 
about the regulation of multiple transcript levels by multiple genetic locations. In such 
an analysis, when an eQTL encloses the physical location of the gene for that 
transcript, it is likely that the genetic variation resides in or close to the gene itself (cis-
QTL). On the other hand, if an eQTL does not map to the physical location of the gene 
for that transcript, it is likely that the genetic variation is caused by other genes (trans-
QTL) (Drake et al. 2006). An example of a trans-QTL could be a genetic variation in a 
transcription factor which affects many different genes located elsewhere in the 
genome. In paper III, we performed VRA and genotyping in a F2 generation followed 
by affymetrix analysis in order to study the linkage of the transcript differences to 
specific loci and genes.  
 
 
3.3.3 Congenic Rat Strains (II-IV) 
 
In a congenic strain, a small fragment of the genome of inbred strain B is introgressed 
in the genome of inbred strain A. Thus, strain B contributes to the background 
genome with this fragment in the resulting congenic strain. In this way, phenotypic 
differences that are found between the congenic and background strain A can be 
attributed to the genetic effect of the specific fragment originating from strain B. 
Congenic strains are produced by continuous backcrossing of the F1 generation with 
the inbred strain that is aimed to become the background strain (Fig. 7). Congenic 
strain production can be done in two ways: 1) the traditional approach by selecting 
the individuals containing the desired fragment for further backcrossing and 2) by the 
“speed congenic” method where the whole genome is genotyped and individuals are 
selected both on the desired fragment but also based on the lowest amount of 
contaminating genome from strain A in each generation (Wakeland et al. 1997). The 
first method is slower and it takes at least 10 generations to produce a congenic strain 
while the “speed congenic” method, although faster, it requires more effort in 
genotyping.  
 
In this thesis four congenic strains were used: 1) the PVG-RT1av1 or PVGav1 congenic 
which is an MHC congenic with PVG background but with the MHC region on 
chromosome 20 introgressed from the DA strain (hereafter PVGA), 2) the PVGav1.DA-
Vra4 congenic on PVG background with the Vra4 locus on chromosome 10, that 
includes the Ciita gene, from DA, 3) the DA.PVGav1-Vra4 congenic on DA background 
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with the Vra4 locus from PVG and 4) the DA.PVGav1-Vra1-R5 on DA background with 
the Vra1 locus on chromosome 8 from PVG.      
 
Congenic rat strains are very valuable in forward genetics, when trying to confirm and 
study the effect of a QTL that has previously been identified by other methods (i.e. 
linkage analysis) to affect a disease phenotype. However, a disadvantage of this 
method is that it is very time consuming and sometimes virtually impossible to 
produce a “one-gene” congenics in order to study the effect of a single gene variation. 
In this way, reverse genetics, with the production of transgenic animals can be utilized 
to complement the information derived by congenic strains and to provide formal 
proof of the effect of a specific gene. However, it should be noted that transgenic 
animals that are produced “artificially”, cannot be used alone in the context of 
complex diseases when investigating natural polymorphisms that drive a disease 
phenotype.  
 
 
 
3.4 EVALUATION OF PATHOPHYSIOLOGICAL PATHWAYS 
 
3.4.1 mRNA Identification and Quantification (I-IV) 
 
The regulation of the different effector molecules in various pathophysiological 
pathways is widely studied by the quantification of their mRNA levels. The tissue piece 
that was taken for mRNA quantification was composed of the contused tissue, the 
pericontusional cortex, the hippocampus and part of the thalamus, since these regions 
 
 
  
 
 
Figure 8. Schematic illustration of the 
tissue piece that was taken for mRNA 
quantification.  
As seen in A it contains the contused 
tissue, the pericontusional cortex, the 
hippocampus and part of the thalamus. 
B and C show a 3D illustration in 
coronal and sagittal view respectively. 
The contused tissue is shown in red 
while the pericontusional tissue is 
shown in blue.  
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contain the strongest biological responses to injury in the WDI model (Fig. 8). We used 
two methods to identify and quantify mRNA levels: real-time quantitative polymerase 
chain reaction (qPCR) and Affymetrix arrays. 
  
Real-time quantitative PCR is a simple, fast, accurate and reliable method for 
quantification of mRNA levels of specific molecules. However, a limitation of qPCR is 
that it does not provide information about the cellular localization of the molecules 
studied. After mRNA extraction from the tissue, RNA-dependent DNA polymerases 
called reverse transcriptase are used to create complementary DNA (cDNA). cDNA is 
then detected, amplified and quantified in “real-time” with the use of a fluorescent 
probe/primer (Heid et al. 1996). When studying expression of MHC-II and since the 
MHC region is highly polymorphic, appropriate care was taken to make sure that the 
primer did not display different affinities/avidities for the two RT1B haplotypes. 
Therefore, the RT1Ba primer was designed from a gene region that was identical 
between the two haplotypes (c and av1). A set of reference/housekeeping genes is 
used for normalization in order to compensate for differences in the amount of the 
starting tissue volume. After TBI, HPRT has been shown to be the most stable 
reference gene in the cerebral cortex while GAPDH is the most stable in the 
hippocampus (Cook et al. 2009). We have therefore used a combination of both HPRT 
and GAPDH as reference genes.  
 
The development of chip based screening techniques during the last decade has 
enabled the study of the expression of all exons across the genome by using 
hybridization technology (Lockhart et al. 1996). We used Affymetrix Exon Arrays in our 
studies to obtain quantitative information about the whole transcriptome in the 
tissue, so called global gene expression profiling. The data were then uploaded in the 
Partek® software where they were normalized using Robust Multi-Array Analysis 
(RMA) to account for whole-chip expression levels (Irizarry et al. 2003). This allowed 
for further analysis in order to identify genes and pathways that were differentially 
regulated using Partek® and Ingenuity software®. 
 
 
3.4.2 Protein Identification and Quantification (I-IV) 
 
Quantification of mRNA is not sufficient to provide information about disease related 
molecules as all mRNA is not transcribed into proteins and it is proteins that exert the 
real effect in biological responses. A combination of the qPCR and Affymetrix data 
with protein studies is therefore required. We have used four methods to identify and 
quantify proteins of interest: western blot and immunohistology, for tissue, as well as 
enzyme-linked immunosorbent assays (ELISAs) and Meso Scale Discovery (MSD®) 
Multi-Array, for CSF. All four methods utilize antibodies to identify and quantify the 
targeted proteins. Thus, it is of major importance to verify, as much as possible, the 
specificity of the antibodies used. Western blot is used for quantification of proteins 
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by size separation of the proteins and quantification of the band only of the right 
molecular weight; it can thereby discriminate between specific and unspecific signal. 
However, it does not provide any information about the tissue/cellular localization. 
This is done best with double/multiple-labeling immunofluorescence combined with 
analysis in a confocal microscope; for example with simultaneous staining of the 
protein in question together with a cellular marker protein. On the other hand, 
immunohistology is not considered a good method for quantification of proteins, in 
particular when profile counting and not stereological methodology is used. However, 
this problem can be overcome when large differences are expected/ seen in the 
tissues compared. Quantification should then be done by a blinded observer to avoid 
bias. ELISA is a frequently used, fast and reliable method for quantification of proteins 
particularly in body fluids (Engvall & Perlmann 1971). MSD® Multi-Arrays allows such a 
quantification to be performed on a smaller fluid volume and for multiple targets (Fu 
et al. 2010).  
 
 
3.4.3 Quantification of Immune Cells (I-II) 
 
In order to detect and quantify immune cells in the injured brain we used flow 
cytometry. This method has been widely used to quantify immune cells in the blood or 
dissociated spleen and only a few studies have attempted to quantify immune cells in 
the injured CNS by flow cytometry using fresh dissociated tissue. Flow cytometry is a 
quick and reliable method that has several advantages over traditional methods of 
assessing the cellular inflammatory response after CNS injury (Beck et al. 2010). 
Traditional analyses with immunohistology require preparation of tissue and manual 
counting of immune cells and offer semiquantitative data at best. Furthermore, the 
populations of blood-derived leukocytes can be rapidly quantified and distinguished 
from resident microglia. However, the use of flow cytometry to quantify immune cells 
in the CNS is complicated by lipid/myelin content and debris. These can interfere with 
antibody binding and decrease measurement sensitivity and accuracy. Several 
methods to overcome this problem have been described with the use of different 
gradient systems in order to get rid of the myelin (Stirling & Yong 2008; Tjoa et al. 
2003). In this thesis, we used the Percoll gradient to separate cell populations from 
myelin/debris and the appropriate cell marker antibodies to distinguish and quantify 
the various cell populations. 
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3.5 EVALUATION OF INJURY OUTCOME AND NEURODEGENERATION 
 
3.5.1 Contusion Volume (II) 
 
The outcome of experimental brain contusion was assessed in paper II by 
quantification of the necrotic cavitation produced 18 days after the injury. Serial 
coronal sections were stained with hematoxylin-eosin and the area of the necrotic 
lesion and the ipsilateral to the injury hemisphere were quantified using an image 
analysis system. The percentage of lesion area for each section was calculated using 
the formula: (volume of necrotic lesion)/ (volume of ipsilateral hemisphere) x 100. The 
percentages of all areas were added in every animal to give an estimation of the lesion 
volume. Some concerns have been raised about this method because oedema was 
found in some studies to contribute to an inaccurate estimation of the lesion volume 
(Baskaya et al. 2000). However, the studies are contradicting and our measurements, 
done at 18 days after the injury, should not be influenced by oedema as it is 
considerably reduced at this time point (Elliott et al. 2008). Furthermore, the volume 
of necrotic cavitation has in several reports been found to correlate to behavioral 
deficits and this method is widely used to assess outcome in TBI (Clausen et al. 2005; 
Marklund et al. 2001). 
 
 
3.5.2 Design-Based Stereology (III-IV) 
 
In papers III and IV we used design-based stereology to estimate the degree of 
neuronal cell survival in VRA and TBI respectively. The term stereology was coined for 
the first time in 1961 at the “Foundation of International Society for Stereology” and is 
used to describe a set of methods that help us derive three-dimensional (3D) 
information from two- dimensional objects (2D), such as tissue sections. Stereology 
has been used since the ancient times in astronomy, for example in the heliocentric 
theory of Aristarchus, and has in the latest decades evolved to become the “state of 
the art” when counting structures such as cells in biological samples (Elias et al. 1971). 
It utilizes various sampling schemes, probes and mathematical quantification formulas 
to estimate the length, volume, surface or number of cells in a tissue sample. The 
term “design-based” means that the probes and sampling schemes are designed 
before the actual counting and this is done in such a way that no assumptions are 
made about the geometries of the cells being counted (Schmitz & Hof 2005; West 
2001). Design based stereology has several very important advantages over profile 
tissue section counting. Although it is a time consuming procedure, it is the golden 
standard for making unbiased, accurate and precise estimations when evaluating cell 
structures from 2D tissue samples. Therefore, it enables the detection of small 
differences in the counted objects that are also statistically valid; for a review of the 
advantages of stereology see (Boyce et al. 2010) . 
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In this thesis, sections were cut perpendicular to the long axis of the tissue and they 
were sampled according to the principle of systematic random sampling (Fig. 9 A and 
B). The optical fractionator was used to count neurons with the use of the newCAST 
software (Visiopharm, Hoersholm, Denmark) (Fig. 4C). The subregion of the spinal 
cord or the hippocampus was delineated and the nucleoli of neurons were counted as 
they came into focus when the focus plane was moved downwards (Dorph-Petersen 
et al. 2001; West et al. 1991). Nucleoli were counted using the unbiased counting 
rules for the optical dissector (Gundersen et al. 1988; West 1993). Neurons were 
identified by their heavily stained cytoplasm, large nucleus and single nucleolus. 
Motorneurons were identified by their large soma diameter, polygonal shape and 
prominent nucleus. The nucleolus was used as the counting unit since neurons have 
only one nucleolus (Bjugn & Gundersen 1993; Penas et al. 2009).    
 
 
 
Figure 9. Schematic illustration of the design based stereology procedure used in paper IV to estimate 
the numbers of neurons in the hilus: A) The hippocampus ipsilateral to the injury was extracted from 
the brain B) The hippocampus was straightened and then sectioned on a vibratome in 65 µm thick 
sections (black lines). The first section was randomly chosen and every 15th section was kept for 
histological staining and counting of neurons in the hilus. C) An illustration of the optical disector 
principle, used to count cells in the thick hippocampus sections, is shown. Virtual counting boxes 
(disectors) will cover the hilus with a uniform distance between them. The edges of the disector are at a 
certain distance away from the surface to prevent bias due to surface tissue deformations. D) The area 
of interest where cell counting is performed is delineated (here the hilus shown in red). E) The virtual 
counting box (optical dissector) is shown at a certain point on the z-axis. The nucleolus that comes in 
focus (white arrow) is counted. Nucleoli that would touch the green lines would be counted but not 
those that would touch the red lines.   
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 4 RESULTS AND DISCUSSION 
 
4.1 NON-MHC GENES REGULATE SECONDARY INJURY CASCADES 
AND OUTCOME 
 
Strain dependent genetic differences have been recognized for many years to affect 
susceptibility to experimental autoimmune encephalomyelitis (EAE), the animal model 
of MS (Kornblum 1968). Susceptibility to EAE is hierarchically determined by genes in 
the MHC-complex itself but with additional influences also from non-MHC genes 
(Weissert et al. 1998). Studies in non-autoimmune CNS and PNS injury models 
identified both MHC and/or non-MHC genes to regulate the phenotypic outcome 
(Bellander et al. 2010; Birdsall Abrams et al. 2007; Dominguez et al. 2008). In paper I, II 
and IV we studied the impact of non-MHC genes on secondary injury cascades and 
outcome after TBI by performing WDI on the inbred rat strains DA and PVGA that 
share the same MHC complex (RT1av1) (Fig. 10 A).  
 
Using affymetrix we performed global expressional profiling of injured brains at 1 
day post-injury (1 DPI). We found that variation in the expression of around one 
third of the more than 27000 examined transcripts could be accounted for by non-
MHC genes, if differences between naïve animals were also included. Analyses of 
the microarray data with the Ingenuity software showed that inflammation was one 
of the top biological functions regulated by both strain and injury. Analyses were 
also performed to search for pathways differing between the two strains after TBI. 
This revealed glutathione metabolism to be the top regulated pathway, while the 
complement system was the top regulated inflammatory pathway. In parallel, our 
experiments in a model of nerve axotomy (VRA) suggested Gsta4 to be a candidate 
gene regulating neurodegeneration between the two strains. Subsequent studies 
were thus focused on inflammatory (paper I and II) and glutathione (paper III and IV) 
related mechanisms suggested to be regulated by non-MHC genes.     
 
Immune cell influx and activations was studied using flow cytometry. The DA rat 
displayed higher numbers of infiltrating granulocytes and NK cells (in particular CD161 
bright) in the brain at 1 DPI. Although the mean numbers of monocytes/macrophages 
were also higher in the DA strain, it did not reach statistical significance, while the 
number of T lymphocytes did not differ. At the same time-point a stronger host tissue 
response, as measured by numbers of activated microglia, was also seen in the DA 
strain. At a later time-point (6 DPI) the numbers of blood derived leukocytes did not 
differ between the strains except for macrophages that were more numerous in the 
DA. However, activation of microglia was much more pronounced in the DA strain 
while it remained virtually the same in the PVGA strain. Thus, a kinetic analysis reveals 
a strong immune cell response in the DA strain characterized by a profound infiltration 
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of granulocytes and NK cells early after injury, which is followed by a strong activation 
of microglia. In contrast, the PVGA strain reveals a more moderate response in all 
aspects of the immune cell response (Fig. 10 B). At 18 days after TBI, the numbers of 
activated macrophages and microglia were decreased and though higher numbers 
were observed in the DA strain, this did not reach statistical significance. However, the 
percentage of T lymphocytes in DA was significantly higher than the PVGA at 18 DPI.    
 
As the complement system was the top regulated pathway between the two strains, 
we looked further into it to characterize the differences and also the role of the 
complement system in our model. Using RT-PCR we found that the complement 
factors C1q, C3 and Itgam/CD11b (complement receptor 3, CR3) were more expressed 
in the DA strain both in naïve state and at 1 and 6 DPI. These differences were 
increased with time from naïve -> 1DPI -> 6 DPI and the kinetics was similar to the 
kinetics of microglia activation in both strains (Fig. 10 B and C). This similarity was 
particularly observed for C1q and C3 while CD11b displayed a decline in relation to the 
microglia kinetics. This can possibly be explained by the decline in numbers of 
macrophages at 6 DPI, since these cells also express CD11b. The exact cell origin of C3 
production was not examined here. However, a previous study in the same TBI model 
utilizing in situ hybridization has shown that C3 is produced by microglia in the WDI 
model (Bellander et al. 1996). Furthermore, the similarities in C3 – microglia kinetics 
and the fact that we found more microglia cells that stained for C3 in the thalamus in 
the DA strain points towards a microglial production of C3 also in our experiments.  
 
The complement system exerts multiple roles in CNS diseases with both healing and 
deleterious characteristics; reviewed in many articles (Elward & Gasque 2003; Francis 
et al. 2003; Morgan et al. 1997; Perry & O'Connor 2008; Veerhuis et al. 2011). 
Complement factor fragments (C1q, C3b, iC3b) can bind to receptors (CR3/CD11b) on 
apoptotic cells and thereby facilitate their phagocytosis and promote healing. On the 
other hand, they can produce the membrane attack complex (MAC) that attaches to 
the cell membranes to promote lysis, attract pro-inflammatory cells to the injured 
tissue (C5a) and promote synaptic striping (C1q, C3). In our experiments, utilizing 
confocal microscopy, we provide evidence of both the tagging function of C3 and lytic 
function of MAC on neurons following TBI. Thus, we saw a C3 and MAC dot-like 
staining of neurons in the pericontusional cortex. This is in accordance with previous 
studies in the WDI model and human TBI showing C3d and C9 to stain neurons at the 
vicinity of the lesion (Bellander et al. 1996; Bellander et al. 2001). However, in our 
studies, C3 and MAC did not only stain neurons in the vicinity of the lesion but also 
stained neurons and neuronal axons in the hippocampus providing evidence of a more 
remote activity of C3 and MAC, possibly regulated by a local production of 
complement factors. This notion is supported by the observation that a diffuse C3 and 
MAC staining, that was present at 1 DPI and possibly originated from blood derived 
complement factors, was diminished at 6 DPI.    
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Figure 10. Strain regulation and kinetics of secondary injury cascades by non-MHC genes (A). B) Strain 
differences and kinetics in leukocyte infiltration and microglia activation at 1 and 6 DPI. C) Strain 
differences and kinetics of C1q, C3 and CD11b expression. D) Strain differences and kinetics of NFL levels 
in rat CSF. The graphs in B-D were produced, using the mean numbers per strain and time-point from 
paper I, to illustrate the kinetics for each strain. The number of leukocytes and activated microglia in 
naïve animals are virtually zero (unpublished data from the lab). Numbers for individual rats are shown 
in the graphs in paper I. * on DA depicts statistically significant differences compared to PVGA at a 
certain time-point.     
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Neuronal/axonal injury and outcome was assessed by various methods: 1) 
Neurofilament light (NFL) level quantification in the CSF in paper I; 2) Lesion volume 
quantification in paper II; 3) Estimation of the numbers of surviving neurons in the 
hilus, by using design-based stereology, in paper III.  
 
CSF NFL levels are increased in EAE (Norgren et al. 2005) and correlate to axonal 
damage and disease severity in MS (Norgren et al. 2004; Salzer et al. 2010; 
Teunissen et al. 2005). Also, CSF NFL levels correlate to the degree of disease 
progression in amyotrophic lateral sclerosis (Tortelli et al. 2012). The kinetics of CSF – 
NFL levels was the same in the two strains at the examined time points. However, we 
found that the DA strain displays considerably higher levels of NFL compared to PVG 
at all time-points and especially at 1 and 6 DPI after TBI (Fig.10 D). Thus, more severe 
neuronal/axonal injury was observed in the DA strain. This is in accordance with our 
findings that more neurons survive in the hilus of the PVGA rat at 30 DPI. Surprisingly, 
when we counted the lesion volumes at 18 DPI, we found that DA rats displayed 
smaller contusion volumes than PVGA rats. Although a high degree of variation was 
observed, particularly in the PVGA strain, it did reach statistical significance. This is 
thus contradicting the results of higher CSF-NFL levels and less neuronal number 
estimates in the DA rat. Two possibilities, apart from the difference in time-points and 
methodological aspects, may underlie this apparent contradictory finding. First, a 
possible higher rate of proliferation and activation of glia cells in the DA strain might 
have contributed to smaller lesion volumes. If this is true, it raises a concern about the 
validity of this method as a measure of outcome, especially when different animal 
strains are studied but also when treatment that affects the glial response after TBI is 
used. A second possible explanation is that cortical neurons differ from hippocampal 
neurons with regards to cell death mechanism and might be differentially regulated 
between the strains. This is supported by the findings of Wennersten et al that 
neurons in the lesion display a necrotic morphology, in the pericontusional cortex 
both a necrotic and apoptotic morphology and in the hippocampus only apoptotic 
morphology in the WDI model (Wennersten et al. 2003). It might thus be speculated, 
that a higher immune cell influx in the DA strain results in a more effective removal of 
necrotic cells from the cortex while more effective mechanisms in the PVGA strain 
save hippocampal neurons from apoptosis. Nevertheless, the combined finding of 
higher NFL levels early and a later augmented loss of hippocampal neurons strongly 
indicate that the DA response is associated with a deleterious outcome with regard to 
nerve cell survival both in the short and medium term after experimental TBI. 
 
In summary, we have shown that non-MHC genes regulate secondary injury cascades, 
particularly neuroinflammation and neurodegeneration. Several questions arise from 
this; some of them have been explored to a certain extent and are addressed in the 
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following sections: 1) What is the role of MHC-genes (4.2); 2) What are the specific 
loci/genes and what do they regulate (4.2 and 4.3). 
 
 
 
4.2 MHC GENES ACCOUNT FOR STRAIN DIFFERENCES IN MHC-II 
PRESENTATION WITH A SMALLER CONTRIBUTION FROM CIITA 
AT THE TRANSCRIPTION LEVEL  
 
In paper I we found substantial differences in the numbers of microglia and 
monocytes/macrophages that present MHC-II on their surface at 6 DPI, and this was 
also true for microglia at 1 DPI. We also saw that the DA strain has higher levels of 
expression of the invariant chain CD74 and RT1Bα compared to PVGA (paper II). 
Thus, the quantitative differences in MHC-II molecules could likely be ascribed to a 
non-MHC regulation of their production at the transcription level. Studies in bare 
lymphocyte syndrome, a hereditary syndrome where cells lack the ability to produce 
MHC-II, and experiments on Ciita-deficient mice, have shown Ciita to be the master 
regulator of MHC-II expression (Chang et al. 1996; Steimle et al. 1993). In turn, 
expression of Ciita is highly complex and is cis-regulated involving four different 
promoters (Muhlethaler-Mottet et al. 1997). In paper II, we hypothesized that the 
non-MHC gene that regulated MHC-II presentation between the DA and PVGA strains 
was Ciita. Indeed, using two reciprocal congenic strains containing the PVG Ciita 
haplotype on DA background and the DA Ciita haplotype on PVGA background, we 
found that variation in the Ciita haplotype regulates MHC-II expression with a 
subsequently similar quantitative effect on MHC-II presentation (Fig. 11). This is in 
accordance with previous findings in the VRA model that show Ciita to be the main 
regulator of MHC-II presentation (Lidman et al. 2003).  
 
Antigen presentation by MHC class II molecules in the CNS has been studied mainly in 
MS and its animal model EAE in order to disclose mechanisms of autoimmunity. The 
HLA exerts the by far strongest genetic effect on disease susceptibility, which is also 
supported by rat studies in EAE (Gourraud et al. 2012; Weissert et al. 1998). However, 
there are now indications that the HLA might also affect primarily non-autoimmune 
diseases. MHC genes affect neuropathic pain in an experimental model of nerve injury 
and some studies have shown a possible association of single-nucleotide 
polymorphisms (SNPs) located within HLA to Parkinson’s and Alzheimer’s disease 
(Ahmed et al. 2012; Dominguez et al. 2008; Guerini et al. 2009). In paper II we studied 
the effect of MHC-gene variation in TBI. This was done by using the PVG rat, which is 
homozygous for the c alleles (RT1c) and the congenic PVGA that is homozygous for the 
av1 (RT1av1). We first studied the expression of the class II invariant chain (Cd74) and 
the α chain of RT1B and found no regulation by MHC genes. Surprisingly, when we 
stained for RT1B (OX6) we found major differences with more RT1B staining on PVG 
rats with the RT1av1 haplotype and this finding was replicated using flow cytometry. 
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Thus, we found that MHC genes account for quantitative differences in MHC-II 
presentation after TBI at the protein level. The highly polymorphic nature of MHC-
genes (see 1.1.4) and the complexity of the MHC-II antigen presentation pathway 
make it difficult to identify the specific gene that accounts for the strain differences 
and also to find exactly where in the pathway it exerts its effect. The MHC-II 
presentation pathway is shown in figure 11: Newly synthesized MHC II αβ dimers 
assemble in with the chaperone invariant chain (Ii). Ii inserts its class II-associated Ii 
peptide (CLIP) within the peptide-binding site of the dimer in order to stabilize and 
protect the site from interacting with other peptides. The αβ-CLIP complexes are 
transported towards sites of antigen binding where the phagocytosed and processed 
antigen displaces CLIP and enters the antigen binding peptide. The αβ-peptides are 
then transported towards the membrane for MHC-II presentation or towards the 
lysosomes for degradation. MHC-II surface molecules can also be internalized and 
transported for degradation. Thus, the amount of MHC-II surface presented 
molecules depends on the whole turnover including the degradation phase and not 
only on the production of αβ-peptide complexes (Fig. 11) (Castellino et al. 1997; 
Villadangos et al. 2005).  
 
 
 
Figure 11. The major histocompatibility complex class II (MHC II) antigen-presentation pathway   
regulated by the Ciita and MHC-complex after TBI; as discussed in the text. 
 
 
We did not find differences between the RT1c and RT1Av1 haplotypes in RT1Ba and 
Cd74 expression, thereby excluding an effect at the level of transcription. Also, we did 
not find any overt differences in terms of microglia/monocyte numbers and activation 
(as shown by CD11b and Mrf1 expression analysis and CD11b+ cells), astroglial 
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response (as shown by Gfap expression analysis), TNF production (as shown by Tnf 
expression analysis), Ager/RAGE formation and RT1D presentation (OX17 
immunohistochemistry, unpublished results). Furthermore, flow cytometry matched 
the results of immunohistochemistry and since it was performed on non 
permeabilized cells, it should imply that the differences in MHC-II numbers concern 
surface presented and not intracellular/internalized MHC-II, possibly excluding a 
genetic effect on the degradation phase. Altogether, these findings suggest that the 
regulatory effect is induced by the class II region, possibly due to RT1B-peptide 
binding affinity. This is also supported by the finding that genetic variations between 
the av1 and c haplotype exert only a small effect on MHC-II presentation in rat VRA. A 
possible explanation for this contradiction could thus be that the inherent differences 
between the models result in a diversity of the peptides that are presented on MHC-II 
molecules in the VRA and TBI models, respectively. However, it has to be emphasized 
that these conclusions are based only on indirect evidence and that intra-MHC 
congenic rats should be used in experimental TBI to help us disclose the gene(s) and 
mechanisms that account for the differences. 
 
The differences in MHC-II presentation found between the PVG and PVGA strains can 
be utilized to investigate if autoimmune responses occur after TBI. CD4+ lymphocytes 
can react with MHC-II presented peptides and become activated. This is dependent on 
the degree of APC maturation and the presence of co-stimulatory molecules (Aloisi et 
al. 2000). Microglia are considered to be the professional APCs of the brain while the 
role of astrocytes is controversial (Aloisi et al. 1998; Chastain et al. 2011; Cornet et al. 
2000; Stuve et al. 2002). MHC-II presentation in our model occurs on CD11b+ cells, 
microglia or macrophages, and these cells also express the co-stimulatory molecule 
B7.2, thereby increasing the likelihood for an autoimmune response (Fig. 12). 
    
 
 
 
 
We found more T cells in the PVGA strain compared to PVG at 18 DPI which suggests a 
stronger T cell response for the av1 haplotype. This is in accordance with the larger 
number of MHC-II+ cells present in this strain. However, we cannot exclude that the 
peptides presented by the av1 and c MHC-II molecules differ and result in stronger 
affinities to CD4+ cells thereby affecting their activation status. Higher numbers of T 
Figure 12. Immunohistochemical staining showing 
the presence of B7-2 at the perilesional cortex after 
TBI  
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cells could thus account for a stronger autoimmune response in the PVGA strain. In an 
attempt to disclose an encephalitogenic response in our model we also stimulated 
lymphocytes from cervical lymph nodes with a myelin basic protein derived peptide, 
MBP63-88. This particular peptide was chosen since it has been shown to induce EAE on 
Lewis rats with the av1 or c haplotype, showing that it can bind to MHC-II molecules of 
both haplotypes and thereby elicit an autoimmune response in both the PVG and 
PVGA strains (de Graaf et al. 1999). Recall with MBP63-88 did not give any evidence of 
autoimmunity directed against this peptide. However, this does not exclude 
autoimmunity directed against other peptides, since there is a large repertoire of 
peptides that can elicit an encephalitogenic response in the context of CNS injury 
(Ankeny & Popovich 2009; Fissolo et al. 2009). Although no differences in lesion 
volume could be ascribed to MHC genes, this does not rule out differences in other 
types of outcome measurements such as behavioral and memory tests. 
 
 
 
4.3 NATURALLY OCCURING VARIATION IN THE GSTA4 GENE 
REGULATES NEURODEGENERATION 
 
In paper I, we found the glutathione metabolism pathway to be the most regulated 
transcriptional pathway between the DA and PVGA strains after TBI. At the same time 
we conducted experiments in a rat VRA model to find gene variations that regulate 
neurodegeneration after nerve axotomy. These experiments were based on previous 
work in our laboratory that started some years ago and demonstrated a higher degree 
of neurodegeneration in the DA strain compared to PVGA, with 26% and 50% 
motorneuron survival, respectively for each strain (Lundberg et al. 2001). A 
subsequent study in a DA x PVG intercross pinpointed a locus at chromosome 8 
(VRA1) to regulate neurodegeneration (Lidman et al. 2003). Following from this 
finding, a genetic fragment that corresponds to the Vra1 locus was introgressed from 
the PVGA strain into DA background to produce a congenic strain (DA.PVGav1-Vra1-R3) 
that was indeed shown to display higher motorneuron survival compared to the PVGA 
strain (Swanberg et al. 2009). In paper III, a congenic that narrowed down the 
introgressed PVG fragment to 35 genes (DA.PVGav1-Vra1-R5), still displayed better 
motorneuron survival than the parental DA. Starting from this finding and in parallel 
with our TBI experiments, we tried to find candidate genes residing in the Vra1 locus 
that could regulate motorneuron degeneration. Given that it is very difficult to 
produce one-gene congenics we performed an eQTL mapping in an F2 DA x PVGA 
intercross. The L4 segment was dissected 5 days after VRA and analyzed by Affymetrix 
Exon array for expression profiling of more than 27.000 genes. eQTL mapping revealed 
only one strong cis-regulated gene contained in the R5 fragment, Gsta4. Gsta4 was 
also one of the four genes that were included in the glutathione metabolism pathway 
and were differentially regulated between the DA and PVGA strain after TBI. When we 
performed WDI in DA, PVGA and R5 rats, we found that the estimated number of 
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surviving neurons in the hilus at 30 DPI was higher for the PVGA and R5 strains 
compared to the DA strain. Thus, our studies in VRA and TBI pointed towards Gsta4 to 
regulate neurodegeneration in both models. Gene expression and western blot 
analysis showed that R5 displays higher mRNA and protein levels compared to DA in 
both strains, suggesting that it is the quantity of Gsta4 that regulates the 
neurodegenerative effect. Immunohistochemical investigations showed Gsta4 to be 
present mainly in neurons in the spinal cord and in the brain, particularly in the 
hippocampus. 
 
Gsta4 displays by far the highest capability for detoxifying 4-HNE by catalyzing its 
conjugation to GSH, suggesting that this might be the pathway by which higher levels 
of Gsta4 in neuronal cells lead to a more efficient detoxification of 4-HNE and thereby 
reduced neurodegeneration. This is supported by previous findings that 4-HNE 
increases cell death in neurons, both in vitro and in vivo (Abarikwu et al. 2012; Akude 
et al. 2010; McCracken et al. 2000; Vigh et al. 2005). In our WDI model, we found 4-
HNE immunoreactivity both in the pericontusional area and the hippocampus, 
including neurons, in accordance with previous studies in experimental TBI and 
suggesting that it may contribute to the DA/R5 strain differences in neuronal cell 
loss. This was further corroborated by injecting 4-HNE in the brain of DA and R5 rats, 
where it induced apoptosis in neuronal cells with higher levels of NFL in the DA 
compared to R5. Altogether these results suggest that Gsta4 variation is regulating 
neurodegeneration in experimental TBI. 
 
The toxic activity of 4-HNE has been implicated to induce neuronal cell death in other 
neurodegenerative diseases such as amyotrophic lateral sclerosis, Parkinson’s and 
Alzheimer’s disease (Butterfield et al. 2010; Fukuda et al. 2009; Pedersen et al. 1998; 
Perluigi et al. 2005; Sultana et al. 2012; Yoritaka et al. 1996) and detection of 4-HNE in 
the CSF of patients with these disorders has been previously reported (Selley 1998; 
Selley et al. 2002; Simpson et al. 2004). In paper IV, we detected 4-HNE-adducts to be 
present in human pericontusional tissue, showing that the Gsta4 – 4-HNE pathway 
might also be of relevance in human TBI. We then put a large effort to detect 4-HNE in 
CSF of experimentally contused rats and in the CSF of TBI patients and controls. The 
protocols have also included CSF from MS and amyotrophic lateral sclerosis ALS as 
references. First, a commercial ELISA kit was used, which successfully detected 4-HNE-
his complexes in low levels in controls and elevated in TBI as well as MS. However, a 
large run on MS CSF revealed a conspicuous correlation to immunoglobulin index. This 
led to extensive control experiments where we later found that all signal was due to 
unspecific binding to immunoglobulins, and none specific for HNE. This finding is of 
major importance for already published studies where detection of HNE was done 
with the same ELISA kit. A second commercial kit, with a sensitivity of 0,625 ng/ml, 
was also unable to detect a positive signal in the samples. To verify these findings, we 
set up our own Sandwich Elisa with two antibodies: monoclonal mouse anti-HNE as 
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capture antibody and rabbit polyclonal anti HNE as detection antibody. One hundred 
µL CSF was incubated overnight and detection antibody was applied in the same 
amount (1:5000), also overnight. Signal enhancement with avidin-biotin system was 
applied to increase sensitivity. As standard, we used control CSF, incubated with 
purified HNE (Cayman chemicals) and diluted into different concentrations. This 
approach could verify a reliable signal down to 0,5 µM added HNE with a good 
consistency between triplicates, but still no positive signal in any sample, neither 
control nor disease. Incubated CSF was also run with western blot using the above 
mentioned antibodies and both showed a nice spectrum of protein bands in CSF 
incubated with 4-HNE, but failed to identify any 4-HNE positive bands in 
TBI/MS/Control CSF. The CSF used has been carefully taken and immediately 
centrifuged followed by storage at -80°C. Based on these extensive experiments, we 
therefore concluded that it is unlikely that 4-HNE exist in micromolar concentrations 
as previously reported. Perhaps, 4-HNE modified proteins are present at a nano- or 
picomolar concentration, if analyzed by more sensitive methods such as HPLC. 
Alternatively, microdialysis fluid should also be analyzed for 4-HNE, since markers of 
oxidative stress such as 8-iso-PGF2a have been shown to display higher levels in 
microdialysis fluid compared to CSF (Clausen et al. 2012).  
           
Altogether, our findings reveal a natural variation in Gsta4 to regulate 
neurodegeneration in both VRA and experimental TBI and identify the Gsta4 – 4-HNE 
pathway as an interesting candidate for regulating outcome in human TBI. 
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 5 POINTS OF PERSPECTIVE 
 
In summary, this thesis highlights a substantial impact of genetic heterogeneity on 
secondary pathophysiological mechanisms that follow brain trauma and identifies 
specific loci/genes that regulate specific pathways. Below, I try to summarize the most 
essential results and give my personal thoughts as to their relation to current 
knowledge in the field and also to future experiments required to advance the 
findings of this thesis.  
 
 
 
• FORWARD GENETICS IN EXPERIMENTAL TBI 
 
Forward genetics have been mainly used in experimental models of complex diseases 
e.g. rheumatoid arthritis, diabetes and MS, among many others. In complex diseases, 
multiple genes regulate the disease and often these genes exert only a small effect to 
increase the overall disease susceptibility in interplay with environmental factors 
(Pritchard & Cox 2002; Ramos & Olden 2008). In TBI the environmental factor which 
causes the disease, although heterogeneous, is known: head trauma. Most of the TBI 
research has focused on observational or hypothesis-driven mechanistic studies to 
elucidate the secondary cascades that connect the type of head trauma to the 
outcome. Although this has contributed a lot to the understanding of TBI pathology, 
our knowledge is still insufficient. In recent years, results from association studies in 
human TBI suggest also a role for genetic factors, although to what extent is largely 
unknown. This was tested experimentally in this thesis and revealed a substantial 
impact of genetic heterogeneity on TBI pathways and outcome in the rat. With the use 
of forward genetics we identified non-MHC genes to regulate inflammation and 
neuronal/axonal injury, Gsta4 to be a candidate gene that regulates hippocampal 
neuronal loss and MHC-genes and Ciita to regulate MHC-II presentation after TBI. 
Thus, we identified genetic loci and genes which exert genetic effects in pathways that 
are specific for each locus/gene. We can thus confidently say that TBI is a “complex” 
disorder with a substantial contribution of allelic heterogeneities on disease pathways 
and outcome. In this context, some of the findings of this thesis are illustrated in 
figure 13. It should be emphasized that each gene’s and locus contributions could be 
independent of the other or it can be multiplicative as a result of gene-gene 
interactions or even protein-protein interactions (Plomin et al. 2009). Also, even 
though we find significant regulation by certain genes/loci, we do not know if these 
are the genes with the strongest effect. For example data from the Affymetrix 
analyses showed that the DA strain has a limited capability to produce lipocalin-2 
(lcn2) compared to PVGA and this has been verified in ongoing studies. Lcn2 has been 
shown to modulate the phenotype of microglia and astrocytes and has detrimental 
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effects in experimental spinal cord injury (Lee et al. 2007; Lee et al. 2009; Rathore et 
al. 2011). It thus can be of significance in regulating the glia response between the two 
strains. In addition, a large number of other transcripts were differentially regulated 
after injury between the strains. Furthermore, the genes and loci identified here to 
regulate response to TBI might or might not be the same when other strains are 
utilized. For all the above reasons, further studies utilizing the forward genetics 
method in other rat strains and in crossing experiments are therefore encouraged.  
 
 
 
 
Figure 13. Forward genetics were used to dissect the influence of inherent genetic variation on 
secondary cascades and outcome. Inbred rat strains and congenics were studied in experimental TBI. 
The experiments were performed with identical injury parameters for all strains and revealed multiple 
genes/loci that influence specific pathways and outcome.   
 
 
The results from this thesis together with previous studies (Bellander et al. 2010; Reid 
et al. 2010; Tan et al. 2009; Witgen et al. 2006), prove genetic heterogeneity to be one 
of the possible explanations for some of the contradicting results in experimental TBI 
42 
 
investigations. In addition, genetic heterogeneity can possibly regulate response to 
treatment. Hypothetically, one could say that the DA strain could benefit more from a 
pharmacological treatment that targets inflammation or lipid peroxidation than the 
PVG strain, where the same treatment might not lead to a significant improvement. If 
this proves to be the case, it will be of importance to conduct future studies on 
pharmacological agents in both inbred and outbred strains. This should be done in 
order to rule out or identify genetic factors that might regulate response to treatment.   
 
 
 
• NEURODEGENERATION OR NEUROINFLAMMATION 
 
In paper IV, we found that Gsta4 is a candidate gene to regulate 4-HNE mediated 
apoptosis and also neuronal cell death in the hilus. Recent technological 
advancements that enable the production of transgenic rats can now be used to 
investigate if Gsta4 is really the gene and further study its function and effect in TBI.  
We are therefore, in an ongoing study, generating a Gsta4 over-expressing DA rat to 
be tested in the same WDI model. Also, since the toxic activity of 4-HNE has been 
implicated to induce neuronal cell death in other neurodegenerative diseases such as 
amyotrophic lateral sclerosis, Parkinson’s and Alzheimer’s disease, studies of the DA, 
R5 and Gsta4 over-expressing DA rat in models of these diseases are relevant 
(Butterfield et al. 2010; Fukuda et al. 2009; Pedersen et al. 1998; Perluigi et al. 2005; 
Sultana et al. 2012; Yoritaka et al. 1996). Furthermore, our results encourage 
investigations on therapeutic agents, such as fumaric acid esters, which are emerging 
now as possible treatments in MS and can increase Gsta4 expression, via the nuclear 
factor (erythroid-derived 2)-like 2 (nrf2) pathway, also in TBI (Linker et al. 2011; Porritt 
et al. 2012). In addition, pharmacological agents, such as histidine analogues or 
hydrazine derivatives, which scavenge 4-HNE and rescue cells from 4-HNE toxicity, 
might also have an effect in TBI (Galvani et al. 2008; Hall et al. 2010; Tang et al. 
2007). A major part of the toxic activity of 4-HNE is due to its binding to proteins that 
alters their activity and function. In this way, 4-HNE can modify proteins to produce 
neoantigens and facilitate epitope spreading, a concept that is particularly interesting 
in the context of autoimmune diseases (Kurien & Scofield 2008). This role of 4-HNE 
has been studied in rheumatologic diseases, while modification of MOG by another 
aldehyde, MDA, led to a more aggressive EAE disease (Scofield et al. 2005; Wallberg et 
al. 2007). Studies on the role of Gsta4 variability and 4-HNE in EAE and MS are 
therefore also encouraged from an immunological point of view.       
 
In paper I, we find that the DA strain displayed stronger activation of inflammatory 
pathways and also more neurodegeneration compared to PVG. The detrimental 
effects of dysregulated activation of microglia, macrophages, neutrophils and the 
complement system have been previously demonstrated in TBI and can explain the 
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above correlational connection between neurodegeneration and inflammation. 
Furthermore, the finding of an influx of two different subsets of NK cells, differing 
between the rat strains, encourages further studies on the role of NK cells in TBI. 
These subsets have been ascribed different functions with regards to T cell activation 
and cytotoxicity: CD161 bright NK cells show a lower inhibitory activity towards T cell 
activation and a higher cytotoxic activity compared to the CD161 dim NK cells 
(Inngjerdingen et al. 2012; Kheradmand et al. 2008). Based on this finding and on 
recent research, revealing different phenotypes for activated microglia and 
macrophages, one should explore if also qualitative differences in these cells account 
for differences in the inflammatory response between the DA and PVG strain 
(Martinez et al. 2008; Ransohoff & Perry 2009; Saijo & Glass 2011).  
 
In the context of genetic regulation we are not able to confidently say if genetic 
variability acting on neurodegenerative pathways (such as Gsta4) accounts for the 
differences in inflammatory response after TBI (paper IV) or, vice versa, that genetic 
regulation of primarily inflammatory factors accounts for the differences in 
neurodegeneration between the strains (paper I). However, based on our findings and 
on previous studies in VRA and EAE on these strains, the most plausible explanation is 
that genetics regulate both inflammatory and neurodegenerative mediators, which 
then interact at the gene, protein and cellular level to drive the disease phenotype. 
 
 
 
• THE ROLE OF MHC-II PRESENTATION: TBI AND AUTOIMMUNITY 
 
In paper II, we found a quantitative genetic regulation of MHC-II presentation mainly 
by MHC genes, but also by Ciita. Furthermore, T cell infiltration was regulated by MHC 
genes. This should be further explored as to the significance of these findings with 
regard to outcome. MHC-II presentation can lead to activation, anergy or apoptosis of 
CD4+ T cells. This is largely unexplored in the field of CNS trauma as it is generally 
considered that traumatic brain or spinal cord injuries (SCIs) do not lead to 
autoimmunity. However, there are several indications that autoreactive T and B cells 
are generated after CNS injuries. “Signs of autoimmunity” have been shown to occur 
after SCI, TBI and also stroke (Ankeny & Popovich 2009; Ankeny & Popovich 2010; 
Becker et al. 2011; Cox et al. 2006). One study showed that T cells obtained from 
patients with TBI can react towards myelin as a sign of autoimmunity (Cox et al. 2006). 
In addition, some reports have shown the presence of autoantibodies in the sera of 
patients with TBI providing indirect evidence about the function of lymphocytes    
(Lopez-Escribano et al. 2002; Prochazka et al. 1971; Skoda et al. 2006). We also, in a 
previous study, found autoantibodies in the serum of experimentally contused rats 
(Rudehill et al. 2006).  Similarly the existence of autoreactive T cells and production of 
autoantibodies have been demonstrated in patients with SCI (Davies et al. 2007; 
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Hayes et al. 2002). The group of Popovich has also demonstrated a destructive role of 
autoreactive T and B cells in experimental SCI where the location of injury and the 
exact timing when activation of these cells is studied play a substantial role (Ankeny et 
al. 2009; Lucin et al. 2007; Popovich et al. 1996). However, animals subjected to 
traumatic CNS injuries do not spontaneously develop clinical signs of autoimmunity. 
This could be because regulatory mechanisms suppress the activity of autoimmune 
cells (Ankeny & Popovich 2010; Kipnis et al. 2002). These autoregulatory mechanisms 
could be surpassed when a new “foreign” antigen is introduced so that autoimmunity 
might occur. When this is done by immunization where adjuvant is used it has been 
shown to have beneficial effects (Schwartz & Kipnis 2001). It is still unclear what the 
result would be if a new antigen is introduced if this happens in an unprimed setting. 
Human studies have been contradicting as to whether TBI increases the risk for MS 
(Goldacre et al. 2006; Kang & Lin 2012; Pfleger et al. 2009; Poser 1994).  
 
 
 
Figure 14. Example of a translational approach from experimental TBI (paper II) to human TBI. We find 
MHC-II presentation after TBI to be regulated by MHC genes. This could also be investigated in human 
TBI by genotyping in order to explore if HLA polymorphisms influence disease outcome (e.g. functional 
restitution, biomarkers reflecting inflammation).    
 
 
The reasons for this contradiction have been speculated to be the variation in study 
designs, the different ethnicities studied and also differences in local environmental 
factors triggering the disease at a later time point after TBI. One explanation could 
also be that quantitative and/or qualitative differences in MHC-II presented antigens, 
depending on both the genotype (HLA) as shown in our study and also the triggering 
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antigen, which occur after TBI, influence a later re-activation of autoimmunity and risk 
for MS. This is particularly interesting since new data show that the location of initial 
antigen presentation or epitope spreading in MS might occur in the CNS itself and not 
in the periphery (Finsen & Owens 2011; Sosa & Forsthuber 2011). It is thus plausible 
that future studies that investigate the relation of TBI to MS should also explore if a 
certain haplotype in combination with TBI increases the risk for MS in a subpopulation 
of patients (Fig. 14).     
 
 
 
• TRANSLATIONAL INTERPRETATION 
The ultimate goal of investigations performed in experimental TBI is to provide 
information that will increase the understanding of the pathophysiology of the disease 
in humans and lead to successful treatment. 
 
 
Figure 15. Hypothetical model explaining why similar individuals with the same type of injury display a 
different outcome also in treatment studies.  
 
 
It is thus of major importance that the findings of this thesis are further investigated in 
human TBI. In the previous section an example of a future translational study to test 
for the effect of MHC genes in human brain trauma is introduced. Similarly, the role of 
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Gsta4 polymorphism in regulating neurodegeneration as well as the role of 4-HNE as a 
possible disease biomarker should be investigated in human TBI. For the former 
purpose an association study will reveal if Gsta4 is relevant in the human context 
while for the latter purpose the use of more sensitive methods such as HPLC and/or 
analyses in microdialysis fluid instead of CSF might be utilized. 
 
As an overall conclusion, the findings of this thesis show that there is a substantial 
contribution of genetic heterogeneity on disease pathways and outcome after 
experimental TBI. This, when translated to the human context, can explain why similar 
individuals with the same type of injury present different outcomes after TBI and 
might also affect response to treatment (Fig. 15). For example, it cannot be excluded 
that treatment with corticosteroids, shown to have detrimental effects in the CRASH 
study, can have beneficial effects for a subgroup of TBI patients with a genetically 
regulated more vigorous or dysregulated inflammatory response (Edwards et al. 2005; 
Roberts et al. 2004). This underscores the need for a GWAS that can reveal genetic 
polymorphisms relevant for human TBI outcome and also for finding disease 
biomarkers that reflect activation of specific pathways, in turn of importance for 
developing more efficient individualized therapies.   
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